Stage IIIA-N2 NSCLC: A review of its treatment approaches and future developmentsVAN MEERBEECK, Jan P; SURMONT, Veerle F. M.Lung cancer. 2009, Vol 65, Num 3, pp 257-267, issn 0169-5002, 11 p.Article

Novel treatment options in stage I non-small-cell lung cancerTARASEVYCH, Svitlana; LAUWERS, Patrick; VANDAELE, Frederik et al.Expert review of anticancer therapy. 2014, Vol 14, Num 9, pp 1007-1020, issn 1473-7140, 14 p.Article

Quantitative Perfusion Scintigraphy or Anatomic Segment Method in lung cancer resectionHOLVOET, Tom; VAN MEERBEECK, Jan P; VAN DE WIELE, Christophe et al.Lung cancer. 2011, Vol 74, Num 2, pp 212-218, issn 0169-5002, 7 p.Article

Malignant pleural mesothelioma: The standard of care and challenges for future managementVAN MEERBEECK, Jan P; SCHERPEREEL, Arnaud; SURMONT, Veerle F et al.Critical reviews in oncology/hematology. 2011, Vol 78, Num 2, pp 92-111, issn 1040-8428, 20 p.Article

Consensus report : Pretreatment minimal staging and treatment of potentially resectable malignant pleural mesotheliomaVAN MEERBEECK, Jan P; BOYER, Michael.Lung cancer. 2005, Vol 49, pp S123-S127, issn 0169-5002, SUP1Conference Paper

Small-cell lung cancerVAN MEERBEECK, Jan P; FENNELL, Dean A; DE RUYSSCHER, Dirk K. M et al.Lancet (British edition). 2011, Vol 378, Num 9804, pp 1741-1755, issn 0140-6736, 15 p.Article

The role of gemcitabine in the treatment of malignant mesotheliomaKINDLER, Hedy Lee; VAN MEERBEECK, Jan. P.Seminars in oncology. 2002, Vol 29, Num 1, pp 70-76, issn 0093-7754Article

Esophageal endoscopic ultrasound with fine-needle aspiration with an on-site cytopathologist : High accuracy for the diagnosis of mediastinal lymphadenopathyTOURNOY, Kurt G; PRAET, Marleen M; VAN MAELE, Georges et al.Chest. 2005, Vol 128, Num 4, pp 3004-3009, issn 0012-3692, 6 p.Article

Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancerNEYMARK, Niels; LIANES, Pilar; SMIT, Egbert F et al.PharmacoEconomics (Auckland). 2005, Vol 23, Num 11, pp 1155-1166, issn 1170-7690, 12 p.Article

Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesotheliomaVAN KLAVEREN, Rob J; AERTS, Joachim G. J. V; DE BRUIN, Hein et al.Lung cancer. 2004, Vol 43, Num 1, pp 63-69, issn 0169-5002, 7 p.Article

Progression-free survival rate as primary end point for phase II cancer clinical trials : Application to mesothelioma-the EORTC lung cancer groupFRANCART, Julie; LEGRAND, Catherine; SYLVESTER, Richard et al.Journal of clinical oncology. 2006, Vol 24, Num 19, pp 3007-3012, issn 0732-183X, 6 p.Article

Multimodal management of malignant pleural mesothelioma: where are we today?VAN SCHIL, Paul E; OPITZ, Isabelle; WEDER, Walter et al.The European respiratory journal. 2014, Vol 44, Num 3, pp 754-764, issn 0903-1936, 11 p.Article

Mediastinoscopy vs Endosonography for Mediastinal Nodal Staging of Lung Cancer: A Randomized TrialANNEMA, Jouke T; VAN MEERBEECK, Jan P; DE RYCK, Frederick et al.JAMA, the journal of the American Medical Association. 2010, Vol 304, Num 20, pp 2245-2252, issn 0098-7484, 8 p.Article

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitorsROLFO, Christian; GIOVANNETTI, Elisa; TARON, Mìquel et al.Cancer treatment reviews. 2014, Vol 40, Num 8, pp 990-1004, issn 0305-7372, 15 p.Article

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)O'BRIEN, Mary E. R; GAAFAR, Rabab M; HASAN, Baktiar et al.European journal of cancer (1990). 2013, Vol 49, Num 13, pp 2815-2822, issn 0959-8049, 8 p.Article

EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopyTOUMOY, Kurt G; RINTOUL, Robert C; VAN MEERBEECK, Jan P et al.Lung cancer. 2009, Vol 63, Num 1, pp 45-49, issn 0169-5002, 5 p.Article

Unexpected response of a pulmonary blastoma on radiotherapy: a case report and review of the literatureSURMONT, Veerle F; VAN KLAVEREN, Rob J; NOWAK, Peter J. C. M et al.Lung cancer. 2002, Vol 36, Num 2, pp 207-211, issn 0169-5002, 5 p.Article

Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancerVAN MEERBEECK, Jan P; KRAMER, Gijs W. P. M; SPLINTER, Ted A. W et al.Journal of the National Cancer Institute. 2007, Vol 99, Num 6, pp 442-450, issn 0027-8874, 9 p.Article

Quality assurance of thoracic radiotherapy in EORTC 08941 : A randomised trial of surgery versus thoracic radiotherapy in patients with stage IIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapyKRAMER, Gijsbert W. P. M; LEGRAND, Catherine L; GIACCONE, Giuseppe et al.European journal of cancer (1990). 2006, Vol 42, Num 10, pp 1391-1398, issn 0959-8049, 8 p.Article

Improving the specificity of fluorescence bronchoscopy for the analysis of neoplastic lesions of the bronchial tree by combination with optical spectroscopy: preliminary communicationBARD, Martin P. L; AMELINK, Arjen; SKURICHINA, Marina et al.Lung cancer. 2005, Vol 47, Num 1, pp 41-47, issn 0169-5002, 7 p.Article

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma : An intergroup study of the european organisation for research and treatment of cancer lung cancer group and the national cancer institute of CanadaVAN MEERBEECK, Jan P; GAAFAR, Rabab; MANEGOLD, Christian et al.Journal of clinical oncology. 2005, Vol 23, Num 28, pp 6881-6889, issn 0732-183X, 9 p.Article

Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validationBAKTIAR, Hasan; LAURENT, Greillier; O'BRIEN, Mary E. R et al.European journal of cancer (1990). 2014, Vol 50, Num 16, pp 2771-2782, issn 0959-8049, 12 p.Article

Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in MesotheliomaHOLLEVOET, Kevin; NACKAERTS, Kristiaan; VAN MEERBEECK, Jan P et al.American journal of respiratory and critical care medicine. 2010, Vol 181, Num 6, pp 620-625, issn 1073-449X, 6 p.Article

Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapySENAN, Suresh; BURGERS, Sjaak; VAN MEERBEECK, Jan P et al.International journal of radiation oncology, biology, physics. 2002, Vol 54, Num 4, pp 999-1006, issn 0360-3016, 8 p.Article

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus Gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the european organization for research and treatment of cancer lung cancer group: EORTC 08975SMIT, Egbert F; VAN MEERBEECK, Jan P. A. M; NEYMARK, Niels et al.Journal of clinical oncology. 2003, Vol 21, Num 21, pp 3909-3917, issn 0732-183X, 9 p.Article